Equities analysts forecast that Sage Therapeutics, Inc. (NASDAQ:SAGE) will announce sales of $1.86 million for the current fiscal quarter, according to Zacks. Nine analysts have made estimates for Sage Therapeutics’ earnings. The highest sales estimate is $2.80 million and the lowest is $500,000.00. Sage Therapeutics reported sales of $1.96 million during the same quarter last year, which suggests a negative year over year growth rate of 5.1%. The company is expected to announce its next earnings results before the market opens on Wednesday, February 24th.
According to Zacks, analysts expect that Sage Therapeutics will report full year sales of $7.04 million for the current fiscal year, with estimates ranging from $5.50 million to $8.67 million. For the next fiscal year, analysts forecast that the business will report sales of $170.37 million, with estimates ranging from $9.71 million to $900.10 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Sage Therapeutics.
SAGE has been the topic of a number of recent analyst reports. William Blair reiterated a “buy” rating on shares of Sage Therapeutics in a research report on Friday, December 4th. Morgan Stanley cut their target price on Sage Therapeutics from $85.00 to $83.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 1st. Bank of America raised their target price on Sage Therapeutics from $72.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, November 16th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell cut their price objective on Sage Therapeutics from $100.00 to $93.00 in a research report on Tuesday, December 1st. Finally, BMO Capital Markets cut Sage Therapeutics from an “outperform” rating to a “market perform” rating and set a $95.00 target price for the company. in a report on Friday, January 22nd. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $80.05.
Sage Therapeutics stock traded up $0.42 during mid-day trading on Thursday, hitting $81.51. The company had a trading volume of 11,401 shares, compared to its average volume of 478,069. Sage Therapeutics has a 12-month low of $25.01 and a 12-month high of $98.39. The company’s fifty day moving average is $85.97 and its 200-day moving average is $71.71. The company has a market capitalization of $4.24 billion, a price-to-earnings ratio of -7.83 and a beta of 2.23.
Sage Therapeutics Company Profile
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases.
Further Reading: Resistance Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.